ERNEST HAWK to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications ERNEST HAWK has written about Randomized Controlled Trials as Topic.
Connection Strength
0.254
-
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22; 117(16):2104-13.
Score: 0.044
-
The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):185-7.
Score: 0.041
-
Do statins prevent cancer? Nat Clin Pract Oncol. 2006 Sep; 3(9):478-9.
Score: 0.040
-
A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):101-11.
Score: 0.038
-
Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002 Aug 07; 94(15):1126-33.
Score: 0.030
-
Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30.
Score: 0.026
-
Statins and cancer prevention. Nat Rev Cancer. 2005 Dec; 5(12):930-42.
Score: 0.009
-
Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1250-2.
Score: 0.009
-
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9.
Score: 0.008
-
Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus. 2003; 16(3):177-86.
Score: 0.008